117 related articles for article (PubMed ID: 7051723)
1. Therapeutic effect of tolbutamide in non-insulin dependent diabetes mellitus (NIDDM). Relation to beta-cell function.
Damsgaard EM; Faber O; Frøland A; Iversen S
Acta Endocrinol (Copenh); 1982 Jul; 100(3):416-20. PubMed ID: 7051723
[TBL] [Abstract][Full Text] [Related]
2. Propranolol does not inhibit sulphonylurea-stimulated insulin secretion in patients with non-insulin dependent diabetes mellitus.
Groop L; Tötterman KJ
Acta Endocrinol (Copenh); 1982 Jul; 100(3):410-5. PubMed ID: 7051722
[TBL] [Abstract][Full Text] [Related]
3. A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy.
Wolffenbuttel BH; Weber RF; van Koetsveld PM; Weeks L; Verschoor L
Diabet Med; 1989 Aug; 6(6):520-5. PubMed ID: 2527134
[TBL] [Abstract][Full Text] [Related]
4. [Fasting blood glucose, glycohemoglobin and urinary glucose excretion in non-insulin-dependent patients with diabetes mellitus].
Damsgaard EM; Faber O; Frøland A; Iversen S
Ugeskr Laeger; 1982 Aug; 144(32):2342-4. PubMed ID: 6755848
[No Abstract] [Full Text] [Related]
5. Comparison of tolbutamide and metformin in elderly diabetic patients.
Josephkutty S; Potter JM
Diabet Med; 1990 Jul; 7(6):510-4. PubMed ID: 2142054
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus.
Park SW; Ihm SH; Yoo HJ; Park JY; Lee KU
Diabetes Res Clin Pract; 1997 Sep; 37(3):165-71. PubMed ID: 9306037
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of sulphonylurea and insulin therapy in non insulin dependent diabetics who had failed on diet therapy alone.
Samanta A; Burden AC; Kinghorn HA
Diabetes Res; 1987 Apr; 4(4):183-5. PubMed ID: 3304783
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB; Bray GA
Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
[TBL] [Abstract][Full Text] [Related]
9. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
Cusi K; Cunningham GR; Comstock JP
Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
12. No effect of propranolol and metoprolol on tolbutamide-stimulated insulin-secretion in hypertensive diabetic and non-diabetic patients.
Tötterman KJ; Groop LC
Ann Clin Res; 1982 Aug; 14(4):190-3. PubMed ID: 6762846
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of secondary failure to tolbutamide therapy.
Jerums G; Ennis GC; Miller M
Aust N Z J Med; 1974 Oct; 4(5):467-74. PubMed ID: 4616676
[No Abstract] [Full Text] [Related]
14. Toward an integrated phenotype in pre-NIDDM.
Bergman RN; Watanabe R; Rebrin K; Ader M; Steil G
Diabet Med; 1996 Sep; 13(9 Suppl 6):S67-77. PubMed ID: 8894486
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
DeFronzo RA; Goodman AM
N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-term tolbutamide treatment on glucose tolerance and insulin secretion in maturity-onset diabetes without obesity.
Lauvaux JP; Mandart G; Heymans G; Ooms HA
Horm Metab Res; 1972 Mar; 4(2):58-62. PubMed ID: 5028221
[No Abstract] [Full Text] [Related]
17. Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations.
Fineberg SE; Schneider SH
Diabetologia; 1980 Jan; 18(1):49-54. PubMed ID: 6988265
[TBL] [Abstract][Full Text] [Related]
18. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
[TBL] [Abstract][Full Text] [Related]
19. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects.
Levy JC; Rudenski A; Burnett M; Knight R; Matthews DR; Turner RC
Diabetologia; 1991 Jul; 34(7):488-99. PubMed ID: 1916054
[TBL] [Abstract][Full Text] [Related]
20. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
